iShares US Pharmaceuticals ETFIHE
IHE
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
5% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 43
1% less funds holding
Funds holding: 141 [Q2] → 140 (-1) [Q3]
7% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 14
2.53% less ownership
Funds ownership: 59.08% [Q2] → 56.55% (-2.53%) [Q3]
7% less capital invested
Capital invested by funds: $402M [Q2] → $373M (-$29.1M) [Q3]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q2] → 1 (-1) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for IHE.
Financial journalist opinion
Neutral
Zacks Investment Research
1 day ago
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the iShares U.S. Pharmaceuticals ETF (IHE), a passively managed exchange traded fund launched on 05/01/2006.
Neutral
Seeking Alpha
1 month ago
IHE Contraction Is Not Justified By Fundamental Data
iShares U.S. Pharmaceuticals ETF is a pharmaceutical ETF offered by iShares, featuring an expense ratio of 0.39% and over $500 million in assets under management. In Q3, the healthcare sector reported earnings that exceeded expectations (+9.3%) and provided strong guidance for CV 2025, according to FactSet. The IHE prices are down 10% from their all-time high, with the next point of control 20% lower, while the maximum drawdown in the past 10 years was 40%.
Neutral
Zacks Investment Research
2 months ago
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
If you're interested in broad exposure to the Healthcare - Pharma segment of the equity market, look no further than the iShares U.S. Pharmaceuticals ETF (IHE), a passively managed exchange traded fund launched on 05/01/2006.
Neutral
Zacks Investment Research
4 months ago
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
Launched on 05/01/2006, the iShares U.S. Pharmaceuticals ETF (IHE) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity market.
Positive
Zacks Investment Research
4 months ago
Pharma ETFs in Focus Post Solid Q2 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
Neutral
ETF Trends
4 months ago
Disruptive Theme of the Week: Playing Defense
When markets correct, it is a good time to revisit which equity market sectors are “defensive” themes. Certain products and services are nondiscretionary in nature that we cannot live without.
Neutral
Seeking Alpha
5 months ago
IHE: Significant Growth Ahead, But Valuation Not Cheap (Rating Downgrade)
IHE invests in large-cap U.S. pharmaceutical stocks with solid long-term growth outlook but high concentration risk. IHE's fund price has been steady with a positive trend in 2024, but its elevated valuation may not make it a good buy currently. Despite being a defensive play in an economic recession, IHE can still experience significant declines due to market sentiment.
Neutral
Zacks Investment Research
6 months ago
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the iShares U.S. Pharmaceuticals ETF (IHE), a passively managed exchange traded fund launched on 05/01/2006.
Positive
Zacks Investment Research
7 months ago
A Look at Pharma ETFs Post Q1 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
Positive
Market Watch
7 months ago
Why investor appetite for commodity funds picked up despite ETF flows broadly seeing ‘pretty big drop' in April
Hello! This week's ETF Wrap digs into the slump in ETF flows in April and investor positioning around commodities as inflation worries persist.
Charts implemented using Lightweight Charts™